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Summary
Clear-cell renal carcinoma is associated with inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. VHL is
the substrate recognition subunit of an E3 ligase, known to target the  subunits of the HIF heterodimeric transcription
factor for ubiquitin-mediated degradation under normoxic conditions. We demonstrate that competitive inhibition of the
VHL substrate recognition site with a peptide derived from the oxygen degradation domain of HIF1 recapitulates the
tumorigenic phenotype of VHL-deficient tumor cells. These studies prove that VHL substrate recognition is essential to
the tumor suppressor function of VHL. We further demonstrate that normoxic stabilization of HIF1 alone, while capable
of mimicking some aspects of VHL loss, is not sufficient to reproduce tumorigenesis, indicating that it is not the critical
oncogenic substrate of VHL.
Introduction migrate in response to hepatocyte growth factor/scatter factor
(HGF/SF) (Koochekpour et al., 1999). Finally, VHL deficient cells
form tumors when implanted in immunocompromised mice (Ilio-von Hippel-Lindau (VHL) disease is an autosomal dominant can-
cer syndrome caused by inactivation of the VHL tumor suppres- poulos et al., 1995).
It is now clear that VHL is the substrate recognition compo-sor gene by mutation, deletion, or hypermethylation. Affected
individuals are at risk to develop highly vascular tumors in a nent of an E3 ubiquitin ligase complex (Duan et al., 1995; Kibel
et al., 1995; Pause et al., 1997, 1999; Kamura et al., 1999) thatnumber of organs, including brain, adrenal, and pancreas, as
well as clear cell tumors of the kidney (Choyke et al., 1995). It targets hypoxia inducible factors 1 (HIF1) and 2 (HIF2)
for ubiquitin-mediated degradation under normoxic conditionsis now clear that 50%–80% of sporadic clear cell renal cell
carcinomas also demonstrate biallelic loss of VHL (Gnarra et (Cockman et al., 2000; Ohh et al., 2000). HIF1 and HIF2
are  subunit isoforms of a heterodimeric transcription factoral., 1994; Foster et al., 1994; Herman et al., 1994), suggesting
a common VHL tumorigenic pathway for the majority of renal responsible for hypoxia-dependent regulation of a number of
genes associated with angiogenesis and erythropoeisis, includ-carcinoma.
Until recently, very little was known about the function of ing VEGF (Forsythe et al., 1996), Glut-1, PDGF, and erythro-
poeitin (Bunn et al., 1998; Semenza and Wang, 1992). AlthoughVHL. Examination of VHL-deficient renal cell carcinoma cell lines
reveals multiple phenotypes that are abrogated by reintroduc- HIF1 and HIF2 share only 48% identity, they both contain a
conserved 15 amino acid minimal VHL binding domain, andtion of wild-type VHL. Biochemically, deficient cells demonstrate
increased transcription of a number of genes, including vascular both bind and activate the same DNA recognition element (Tian
et al., 1997; Flamme et al., 1997). Under normoxic conditions,endothelial growth factor (VEGF) (Siemeister et al., 1996) and
glucose transporter-1 (Glut-1) (Iliopoulos et al., 1996). Deficient key proline residues of HIF are hydroxylated by a recently
described family of oxygen-dependent prolyl hydroxylases (Ep-cells have a disrupted extracellular matrix due to inappropriate
processing of fibrinogen (Ohh et al., 1998) and undergo abnor- stein et al., 2001). Unhydroxylated HIF does not bind VHL,
and thus accumulates in the cell (Jaakkola et al., 2001; Ivan etmal growth in response to serum starvation (Pause et al., 1998).
When grown in a collagen matrix, deficient cells branch and al., 2001). All renal tumor-causing VHL mutants thus far exam-
S I G N I F I C A N C E
Loss or inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene is implicated in more than 60% of sporadic clear cell
renal cell carcinoma cases. VHL forms the recognitions subunit of an E3 ubiquitin ligase, which targets hypoxia inducible factor 
subunit isoforms, HIF1 and HIF2, for ubiquitin-mediated degradation. VHL associated renal cell tumors demonstrate defective
ubiquitination of HIF subunits, suggesting that this function is critical to tumor suppression by VHL. To test this, we blocked binding of
VHL to HIF subunits in renal tumor cells reexpressing VHL and demonstrated recovery of tumor growth in SCID mice, indicating a
crucial role for HIF regulation in tumorigenesis in these cells.
CANCER CELL : April 2002 · VOL. 1 · COPYRIGHT  2002 CELL PRESS 247
A R T I C L E
strated coimmunoprecipitation of HIF1 and VHL, which was
expected on reoxygenation of the lysate (Cockman et al., 2000).
In contrast, interaction between HIF1 and VHL was not de-
tected in lysate prepared from the ODD-GFP transfectant, de-
spite high levels of HIF1. This observation is consistent with
successful competition for VHL binding by ODD-GFP. We were
unable to detect coimmunoprecipitation of ODD-GFP with en-
dogenous VHL from these lysates. To improve detection of
binding between VHL and ODD-GFP, we cotransfected cells
with wild-type VHL. The addition of exogenous VHL enabled
demonstration of ODD-GFP coimmunoprecipitation with VHL
(data not shown) confirming direct binding.
To evaluate transcription of HIF1 target genes, ODD-GFP
was cotransfected with luciferase reporter constructs con-
taining the minimal hypoxia responsive promoter of either eryth-Figure 1. Induction of HIF1 by ODD-GFP in HeLa cells
ropoietin (Figure 2A) or VEGF (Figure 2B). Untransfected HeLaA representative immunoblot demonstrating induction of HIF1 protein in
cells demonstrated low levels of transcription of both reportersuntransfected (UT) cells by exposure to 8 hr of 0.5% O2 (H), and similar
induction in normoxia (N) when the ODD-GFP fusion was present. Corre- in normoxia with 5- to 10-fold increase of luminescence in hyp-
sponding anti-VHL immunoprecipitation (IP) reveals loss of VHL-HIF1 co-IP oxia. Normoxic transcription of both reporters approached hyp-
when ODD-GFP was expressed.
oxic levels when cells were transfected with ODD-GFP but not
with GFP alone, demonstrating that the nondegraded endoge-
nous HIF1 was transcriptionally active in normoxia. ODD-GFP
transfected cells grown in hypoxia did not show any furtherined result in defective ubiquitination of HIF (Cockman et al.,
increase in VEGF reporter transcription, suggesting that the full2000; Ohh et al., 2000). Although HIF1 and HIF2 are the only
hypoxic effect was duplicated by the fusion construct.documented substrates of the VHL E3 ubiquitin ligase, others
Although we had shown that ODD-GFP stabilized HIF1may exist.
protein and induced transcription of hypoxia-responsive genesAlthough stabilization of HIF is consistent with the elevated
by blocking the interaction between HIF1 and VHL, we couldVEGF levels and increased vascularity characteristic of VHL-
not rule out the possibility of alternative mechanisms for these
associated tumors, it is unclear whether all aspects of the phe-
effects, including blockade of an interaction between VHL and
notype associated with VHL loss and reversible by VHL reintro-
another substrate. To specifically address the role of HIF1
duction can be directly attributed to substrate degradation by
protein level regulation in the phenotypes associated with the
VHL. To address this, we competitively inhibited VHL-substrate expression or loss of VHL, we next created a HIF1 mutant that
binding using a peptide derived from the VHL binding domain was unable to bind VHL. Site-directed mutagenesis was used
of HIF1. Expression of the peptide fully recapitulated the tu- to substitute five amino acids of HIF1 within the conserved
morigenic phenotype of VHL negative cells, indicating that VHL- VHL binding domain including proline 564, the target of the HIF
substrate recognition is critical for tumor suppression by VHL. prolyl hydroxylase (Epstein et al., 2001; Ivan et al., 2001). We
We further demonstrate that expression of a HIF1 variant that first introduced this mutation into the ODD-GFP fusion construct
is unable to bind VHL mimics some aspects of VHL loss but is not to confirm that it eliminated VHL binding. The mutation, ODD-
tumorigenic, suggesting that HIF1 is not the critical substrate of GFP(M2), abrogated competitive inhibition of endogenous
VHL for tumor formation. HIF1 degradation (data not shown). Consistent with this find-
ing, VEGF-luciferase reporter activity was not induced above
Results normoxic background levels by the mutant ODD-GFP(M2) (Fig-
ure 2C). Next, we introduced the same mutation into a full-
To competitively inhibit HIF1 binding and degradation by VHL, length HIF1 cDNA, HIF1(M2). HeLa cells cotransfected with
we created a recombinant fusion construct containing the oxy- wild-type HIF1 and the VEGF-luciferase reporter demonstrated
gen-dependent degradation domain (ODD) of HIF1 followed some transcriptional activation, possibly attributable to overex-
by green fluorescent protein (GFP), ODD-GFP. We initially tested pression of HIF1 beyond the capacity of endogenous VHL to
the effect of the construct on HIF1 expression in HeLa cells degrade. Cotransfection with HIF1(M2), however, induced re-
for ease and efficiency of transfection (Figure 1). Untransfected porter activity approaching the high levels seen in hypoxia. This
HeLa cells had no detectable HIF1 in normoxia (lane 1) but demonstrated that although the mutant HIF1 had lost the ability
demonstrated HIF1 induction when grown in 0.5% O2 for 8 to bind VHL, it remained transcriptionally active (Figure 2D).
hr (lane 3). Transient transfection with ODD-GFP stabilized en- We now had two constructs, ODD-GFP and HIF1(M2),
dogenous HIF1 protein to levels approaching those seen in capable of abrogating oxygen-dependent VHL degradation of
hypoxia (lane 2), suggesting that the fusion was effectively pre- HIF1. We next expressed these constructs in the renal cell
venting HIF1 degradation. When ODD-GFP transfected cells carcinoma cell line 786-0 to determine to what extent the VHL-
were grown in hypoxia, no further induction of HIF1 was seen negative phenotype could be reproduced by disruption of HIF
(lane 4), suggesting that hypoxia was not contributing to HIF1 degradation. Matched 786-0 subclones expressing exogenous
induction by alternate pathways. The same four lysates were wild-type VHL (WT) or empty vector (PRC) have been well char-
immunoprecipitated with anti-VHL Ab to assess binding of VHL acterized (Iliopoulos et al., 1995). Of note, 786-0 does not ex-
press detectable levels of HIF1 (Maxwell et al., 1999) but doesto HIF1 or ODD-GFP (lanes 5–8, respectively). Lane 7 demon-
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Figure 2. Induction of downstream HIFa tran-
scription activation by ODD-GFP
A: Coexpression of an erythropoetin-luciferase
reporter (EPO) activity in Hela cells. Note that
ODD-GFP induced transcription levels in nor-
moxia (N) approaching those seen in untrans-
fected cells (UT) exposed to hypoxia (0.5% O2)
for 8 hr (H). B: Coexpression of VEGF-luciferase
and ODD-GFP. Hypoxic levels of VEGF-luciferase
reporter activity were induced by ODD-GFP but
not GFP alone. C: A 5 amino acid alanine substi-
tution in the ODD (M2) prevented transcription
by ODD-GFP. Coexpression of VEGF-luciferase
and full length HIF1 cDNA. D: Exogenous HIF1
minimally induced VEGF-luciferase. Introduction
of the ODD mutation, M2, caused hypoxic levels
of reporter activity. Assays were performed in
triplicate. Bars represent standard deviation of
the mean.
express HIF2, which appears to be identically regulated by without VHL (lanes 1 and 2). ODD-GFP did not induce endoge-
nous HIF1 expression in 786-0 WT cells (data not shown).VHL. Stable retroviral lines expressing high levels of ODD-GFP,
HIF1 was detectable only in cells expressing exogenousGFP alone, or HIF1(M2) were established in both WT and
HIF1(M2) (lane 3). Downstream transcription activity of HIFPRC 786-0 backgrounds. Western analysis of whole cell lysates
was evaluated in the 786-0-derived cell lines by real-time quanti-(Figure 3A) confirmed the stabilization of HIF2 in all PRC-
tative RT-PCR for VEGF (Figure 4). VEGF transcription was in-derived cells (lanes 1–4) in which VHL was absent. In cell lines
duced by ODD-GFP (bar 4) and HIF1(M2) (bar 5), but not bythat expressed wild-type VHL, HIF2was only faintly detectable
GFP alone (bar 3).in normoxia (lane 5), consistent with oxygen-dependent ubiqui-
We next studied the effect of HIF stabilization on anothertin-mediated degradation (Maxwell et al., 1999). Addition of GFP
phenotype associated with the presence or absence of VHL. Italone did not induce endogenous HIF2 levels in normoxia (lane
has been previously demonstrated that in the absence of VHL,8). Nor were endogenous HIF2 levels induced by the full-length
786-0 PRC cells exposed to hepatocyte growth factor/scattermutant HIF1 (lane 6), demonstrating that the mutant HIF1 did
factor (HGF/SF) demonstrate marked branching (Figure 5A).not interfere with normal VHL function. In constrast, endogenous
HIF2 was stabilized in WT cells by the introduction of the
competitive inhibitor, ODD-GFP (lane 7), confirming that the
ODD derived from HIF1 is capable of blocking VHL binding of
HIF2 as well. Western blotting for HIF1 (Figure 3B) confirmed
the absence of detectable protein levels in 786-0 cells with or
Figure 3. Representative immunoblot of 786-0 stable cell lines with wild-type
VHL (WT) or empty vector (PRC) expressing ODD-GFP, GFP, or HIF1(M2) Figure 4. Real-time quantitative RT-PCR for VEGF
Relative cycle thresholds for VEGF amplification. RNA samples were ana-200g lysate per lane. All cells were grown in normoxia except as indicated.
A: Note that endogenous HIF2 was induced by ODD-GFP, but not by GFP lyzed in triplicate. Standard deviation of the mean for each cell line is
indicated.alone or HIF1(M2). B: HIF1(M2) causes normoxic stable expression of HIF1.
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Figure 5. Branching morphogenesis assay
786-0 stable cell lines grown in a colloid matrix
under normoxic conditions for 72 hr. A: PRC dem-
onstrated branching of all cells. B: WT cells ex-
pressing GFP only showed no branching. C: WT
cells expressing ODD-GFP demonstrated a dis-
tinct subpopulation of branching cells. D: Simi-
larly, WT expressing full-length mutant HIF1(M2)
demonstrated branching of a fraction of cells.
E: WT cells in hypoxia demonstrate branching in
the absence of HGF/SF.
Reintroduction of wild-type VHL completely abrogates this phe- Finally, we directly examined the tumorigenic phenotype of
VHL deficient cells. 786-0 PRC cells injected subcutaneouslynotype, resulting in rounded cells (Koochekpour et al., 1999)
(Figure 5B). When ODD-GFP was expressed in 786-0 WT, evalu- into immunocompromised mice form palpable tumors after six
weeks. Reintroduction of WT VHL suppresses this tumorigenication of three high power fields revealed the branching pheno-
type in approximately 50% of the cells (Figure 5C). Incomplete potential (Iliopoulos et al., 1995) leading to delayed formation
of small tumors after 12–13 weeks. Expression of ODD-GFPbranching was attributed to varying levels of expression of the
competitive inhibitor, as reflected by the variation of GFP flo- abrogated the tumor suppressor effect of VHL in WT cells that
were injected into SCID mice (Figure 6A), suggesting that therescent intensity observed between individual cells. These re-
sults suggest that the absence of branching in 786-0 cells is substrate binding site of VHL is essential for its tumor suppres-
sor function. To determine if the tumorigenicity was due todependent on the ability of VHL to recognize its substrates. To
test whether the branching observed in PRC cells could result accumulation of HIF1, we injected mice with WT cells that
expressed HIF1(M2) (Figure 6B). Elevated levels of transcrip-from elevated levels of HIF, we introduced HIF1(M2) into
WT cells. These cells demonstrated distinct branching morpho- tionally active HIF1 in the presence of wild-type VHL did not
reproduce the tumorigenic phenotype, suggesting that HIF1genesis in 25%–30% of the cells (Figure 5D), indicating that
elevated HIF1 in the presence of wild-type VHL does contribute is not the critical target of VHL-mediated ubiquitination for tu-
morigenesis. Indeed, cells expressing HIF1(M2) tended towardto the branching phenotype of 786-0 cells. If stabilization of
HIF alone can lead to branching morphogenesis, then we even lower tumorigenic potential than those expressing wild-
type VHL alone. Cells cultured in parallel maintained expressionwould expect to see the branching phenotype in WT cells ex-
posed to hypoxia. Indeed, hypoxia alone induced clear, though of the mutant HIF1 throughout the duration of the study (data
not shown) with no evidence of increased cell death. Histologicsomewhat less vigorous, branching morphogenesis in nearly
100% of these cells (Figure 5E). examination of the tumors induced by expression of ODD-GFP
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Figure 6. Tumorigenesis assay
SCID mice were subcutaneously injected with 1 million cells as indicated, Figure 7. Histologic examination of mouse tumors
and tumor kinetics plotted weekly. A demonstrates reproduction of the
A demonstrates the classic clear cell pattern of tumors derived from 786-0tumorigenic phenotype by the addition of ODD-GFP but not GFP alone. 5
PRC-GFP. B shows the poorly differentiated histology uniformly observed formice were evaluated for each cell line, and mean cross-sectional area
the WT/ODD-GFP tumors. Three tumors from each cell line were sectioneddetermined. Bars represent standard error of the mean at each time point.
and examined by a pathologist without knowledge of the genotype. TheB shows persistent tumor suppression despite overexpression of HIF1(M2).
histologic pattern was uniform within each cell line.7 mice each were evaluated with PRC and WT/HIF1(M2), and 6 mice were
used for the WT line. Means were calculated using all mice in each set,
and the standard error of the mean is represented by bars.
function of VHL depends upon its ability to target substrates for
ubiquitin-mediated degradation. Using a competitive inhibitor
of the VHL-HIF1 binding site, we demonstrate that substrate(Figure 7) revealed a uniformly poorly differentiated histology,
in contrast the classic clear cell pattern of VHL-associated renal binding is crucial to tumor suppression by VHL.
Our data show that disruption of VHL-HIF binding causescancers. This suggests that loss of some other VHL function, not
essential to tumorigenesis and not dependent upon substrate accumulation of HIF protein in normoxia, with corresponding
increased transcription of the HIF-dependent genes, VEGF andrecognition, may be responsible for clear cell histology or, alter-
natively, that ODD-GFP has other effects in the cell unrelated erythropoietin. This is consistent with the finding that loss of
VHL function results in HIF subunit accumulation in normoxiato its interaction with VHL.
(Ohh et al., 2000; Cockman et al., 2000), and with the observa-
tion that clear cell renal cell tumors demonstrate constitutivelyDiscussion
elevated levels of VEGF, Glut1, and PDGF (Siemeister et al.,
1996), known targets of HIF. We further show that the branchingThe majority of kidney cancers are associated with loss of VHL
tumor suppressor function, but the steps leading to tumorigene- morphogenesis observed in VHL deficient cells can be repro-
duced by inhibition of substrate binding. Branching morphogen-sis are not fully understood. VHL deficient tumor cell lines dem-
onstrate increased expression of hypoxia inducible genes, but esis is known to occur upon HGF/SF stimulation through its
interaction with the MET receptor (Koochekpour et al., 1999).also demonstrate impaired extracellular matrix formation (Ohh
et al., 1998) and undergo branching morphogenesis upon stimu- These results suggest that the branching phenotype of VHL
deficient cells may also occur via HIF stabilization. This islation by HGF/SF (Koochekpour et al., 1999). We now know
that VHL is the substrate recognition subunit of an E3 ubiquitin supported by our finding that hypoxia alone can induce
branching, even in the absence of HGF/SF. These results areligase that targets HIF1 and HIF2 for degradation. All renal
tumor-derived VHL mutations examined result in impaired ubi- consistent with the recent finding that HIF1 induction occurs
as a result of HGF/SF stimulation (Tacchini et al., 2001).quitination of HIF1 (Ohh et al., 2000; Cockman et al., 2000). Our
objective was to determine to what extent the tumor suppressor To date, the only two VHL substrates identified have been
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HIF1 and HIF2,  isoforms of the HIF heterodimeric transcrip- Wiesener et al. reported that HIF2was a stronger transactivator
for VEGF than HIF1 (1998). Similarly, overexpression of VEGFtion factor (Jain et al., 1998). HIF  is an attractive candidate
for a renal cancer oncogene because HIF stabilization results in human hemangioblastomas highly correlated with HIF2 ex-
pression in the stromal cells (Flamme et al., 1998). Giatromano-in elevated transcription of a number of angiogenic and prolifera-
tive genes, including VEGF (Semenza et al., 1999) and TGF  laki et al. also found that HIF2 significantly correlated with
VEGF activation and vascularization in lung tumors (2001). En-(Ananth et al., 1999). Indeed, elevated levels of HIF1 have been
documented in tumors derived from multiple tissues, including dothelial tyrosine kinase 2 is specifically activated by HIF2
(Tian et al., 1997). It is possible that the enhanced angiogeniccolon, breast, lung, skin, ovary, pancreas, prostate, and kidney
(Zhong et al., 1999). Similarly, both HIF1 and HIF2were found profile of HIF2 contributes to a greater tumorigenic potential.
Further, HIF1 and HIF2 demonstrate cell-type specificityto be elevated in non-small cell carcinoma of the lung (Giatroma-
nolaki et al., 2001), hemangioblastomas, and renal tumors (Krieg with limited redundancy (Jain et al., 1998). HIF2 protein is
abundant in vascular epithelium (Tian et al., 1997), particularlyet al., 2000).
To determine if overexpression of HIF1 under normoxic in the capillaries of the brain. HIF2 mRNA levels are elevated
in lung, liver, and kidney glomeruli, and in the smooth muscleconditions can fully explain the tumorigenic phenotype of our
cells, we created a mutant of HIF1 that was not able to bind cells of the uterus (Flamme et al., 1997). Interestingly, high HIF2
mRNA levels have also been found in catecholamine-producingwith VHL. Although the possibility that the mutation introduced
subtle alterations in transcription complex formation cannot be cells of the sympathetic nervous system (Favier et al., 1999).
ruled out, exogenous expression of this mutant did result in Tian et al. reported that mice deficient in HIF2 died in utero
normoxic accumulation of HIF1 protein and did increase acti- due to insufficient circulating catecholamines, despite normal
vation of the VEGF and erythropoietin promoters. Expression vascular development (1998). This is in contrast to the pheno-
of the HIF1 mutant also reproduced branching morphogenesis type of HIF1 knockout mice, which die in utero secondary
despite the presence of wild-type VHL. Our results, however, to neural tube and cardiovascular malformations (Kotch et al.,
demonstrate that constitutive expression of HIF1- alone is not 1999). It is tempting to speculate that if HIF2 is indeed a renal
sufficient to cause tumorigenesis in 786-0 cells reexpressing cancer oncogene, then the pattern of HIF2 abundance may
wild-type VHL. This finding raises several distinct possibilities. be responsible for the observed organ specificity of the VHL
It may be that HIF1 and HIF2 have differential tumorigenic syndrome, particularly vascular tumors of the central nervous
potential, and that it is actually HIF2 that is necessary for tumor system and kidney, and catecholamine-producing pheochro-
maintenance in these cells, or a combination of HIF1 and mocytomas.
HIF2. Alternatively, other as yet unidentified VHL substrates In summary, we have shown that competitive inhibition of
may be responsible for the tumorigenic phenotype. With regard the VHL substrate recognition site completely abrogates the
to the latter, anti-VHL immunoprecipitates from metabolically tumor suppressor function of wild-type VHL protein. Deregu-
labeled cells in the presence of proteasome inhibitors have not lated expression of HIF1, although capable of inducing the
revealed any other potential substrates (Maxwell et al., 1999). biochemical and morphogenic phenotypes of VHL-deficient
Also, RNA array results revealed that the majority of VHL regu- cells, is not sufficient to maintain tumorigenesis. These studies
lated genes are also oxygen responsive (Wykoff et al., 2001), do not rule out the possibility that HIF1 could contribute more
again suggesting that the HIF isoforms are the primary ubiquiti- directly to tumorigenesis in other renal cell carcinomas. It is
nation targets of VHL. Finally, we cannot exclude the possibility worth noting that 786-0 cells do not express HIF1, and that
that our ODD-GFP competitive inhibitor fragment causes tumor- perhaps the ability of specific substrates of VHL to recapitulate
igenesis, not through stabilization of HIF  subunits, but by the VHL loss phenotype is not an intrinsic property of HIF1
competitive inhibition of normal HIF prolyl hydroxylase activity versus HIF2, but rather is dependent upon the tumor cell in
on as yet unidentified substrates. which HIF1 or HIF2 is functioning. The strikingly different
We became aware during the course of this study that other effects of deregulated expression of HIF2 and HIF1 on tumori-
investigators were performing a similar set of experiments using genicity point to the need to define the distinct downstream
the corresponding HIF2 mutant (Kondo et al., 2002 [this issue targets of these two closely related transcription factors and to
of Cancer Cell]). They report that expression of mutant HIF2 determine whether these differences are dependent upon either
in normoxia does rescue the tumorigenic phenotype in tumor the lineage or the mutational history of the cells.
cells transfected with wild-type VHL. Thus, it appears that in
the context of the multiple genetic changes present in these Experimental procedures
tumor cells, stabilization of HIF2 is required for maintenance
Cells and cell cultureof the tumorigenic state. This is consistent with our finding that
HeLa and 786-0 cell lines were maintained in Dulbecco’s modified Eagle’sthe ODD-GFP competitive inhibitor rescued the tumorigenic
medium containing 10% fetal calf serum. 786-0 is a sporadic renal cell
phenotype, since we demonstrated that the ODD was able to carcinoma (RCC) cell line with loss of one VHL allele and inactivation of the
prevent VHL-mediated degradation of endogenous HIF2 in other allele via truncation of the other after amino acid 104. The sublines
normoxia. We suspect that the 786-0 cell line bears other muta- 786-0 (wt) and 786-0 (v) were created by stable transfection of wild-type
VHL or empty vector, respectively, and were a gift from W. Kaelin (Iliopoulostions responsible for tumorigenesis because we find it unlikely
et al., 1995). Transient transfections of HeLa were performed using a 3:1that chronic hypoxia alone is sufficient to form tumors.
ratio of Fugene6 (Roche Molecular Biochemicals, Branchburg, NJ) to totalDespite the fact that both HIF1 and HIF2 are regulated
plasmid DNA. Cells were grown at 37C for 24 hr prior to lysis. For the finalby VHL in normoxia at the protein level (Maxwell et al., 1999),
eight hours of incubation, hypoxic cultures were grown in modular incubator
and that both bind to and activate transcription from the same chambers (Billups Rothenburg, Del Ray, CA) containing an atmosphere of
DNA element (Tian et al., 1997), there is data to suggest that 0.5% O2, 5% CO2, and 94.5% N2. Retroviral plasmids, described below,
were transfected into the Pheonix 293 viral packaging cell line and incubatedthey have somewhat different transcription activation profiles.
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at 32C for 48 hr. The media was then collected and used to infect 105 a rotator. Beads were washed five times in phosphate-buffered saline with
0.05% Tween 20 (PBST). Lysates were resolved by SDS-PAGE using two-recipient cells as described. (Kotani et al., 1994) Briefly, the supernatant
was filtered and supplemented with 4 g/ml polybrene (Sigma) and then faced gels (8% upper half and 12% lower half) and transferred to PVDF
(Immobilon-P; Millipore, Bedford, MA) on a semidry transfer apparatus (Bio-one milliliter was applied to adherent cells. The plate was centrifuged at
1100 rpm (SorvallRT) for 45 min. A second milliliter of viral media was then Rad, Hercules, CA). The filter was then incubated for one hour in PBST with
5% powdered milk, washed three times with PBST, and incubated overnightadded, and centrifugation was repeated. Infected cells were incubated at
32C overnight and then transferred to 37C with fresh media. Selection with at 4C in primary antibody (4 g/ml anti-GFP, 5 g/ml anti-HIF2, 1 g/ml
anti-VHL, or 1 g/ml anti-HIF1) in PBST with 5% powdered milk. After1 g/ml puromycin (Sigma) was started 48 hr later.
three more PBST washes, filters were incubated with secondary antibody
conjugated to horseradish peroxidase (Amersham) in PBS with 1% pow-Plasmids
dered milk for 30 min at room temperature. The filter was washed fivepcDNA3-HIF1, a gift from S. McKnight, contains the HIF1 coding se-
times with PBST and developed by chemiluminescence (Renaissance; NEN,quence, followed by an in-frame c-myc tag, ligated into pcDNA3 (Invitrogen,
Boston, MA).Carlsbad, CA). To obtain the HIF1 fragment consisting of residues 541 to
580, pcDNA3-HIF1 was PCR amplified with primers 5-CGACTCCATGGC
Gene expression assaysTGAAGACACAGAA-3 and 5-AGTCGGCGGCCGCCAACTGATCGAA-3 in-
In HeLa cells, luciferase reporter activity was measured using a luminescencecorporating NcoI and NotI sites, respectively. The product was digested
system (Promega, Madison, WI) as described by the manufacturer. For 786-0with NcoI and NotI and ligated into pCMV/myc/cyto (Invitrogen) to create
lines, total RNA was extracted with Trizol reagent (Life Technologies, Grandan in-frame fusion with c-myc. The resulting vector was then PCR amplified
Island, NY) and subjected to real-time quantitative RT-PCR using the TaqManwith primers 5-GGACTAAGCTTATGGCTGAAGACACA-3 and 5-AGTCGGG
Gold RT-PCR Kit (PE Biosystems, Alameda, CA) with primer-probe setsATCCCAGATCCTCTTCTGA-3, incorporating HindIII and BamHI sites, re-
designed to amplify Glut-1 and VEGF (Bioserve, Laurel, MD). The VEGFspectively, to obtain 541–580/c-myc. This product was digested with HindIII
primers were 5-TACCTCCACCATGCCAAGTG-3 and 5-ATGATTCTGCCCand BamHI and ligated into pEGFP-N3 (Clontech, Palo Alto, CA) to create
TCCTCCTTC-3with probe, 5FAM-TCCCAGGCTGCACCCATGGC-TAMRA-3.an in-frame fusion with enhanced green fluorescent protein (GFP), pEGFP/
Glut-1 primers were 5-GCGGAATTCAATGCTGATGAT-3 and 5-CAGTTTC541–580.
GAGAAGCCCATGAG-3 with probe, 5FAM-CTGGCCTTCGTGTCCGCCGT-A PCR-based site-directed mutagenesis system (Quikchange, Stra-
TAMRA-3. Cycle threshold values were corrected for amplification of atagene, Cedar Creek, TX) was used to replace residues 564–568 of pcDNA3-
GAPDH control primers-probe (VIC) set (PE Biosystems). Reactions wereHIF1 with alanine in two stages. First-stage primers were 5-GGAGATGT
run on the ABI Prism 7000 Sequence Detection System (PE Biosystems)TAGCTCCCTATACCGCAGCGGATGATGACTTCCAG-3 and 5-CTGGAAG
according to the manufacturer’s recommendations.TCATCATCCGCTGCGGTATAGGGAGCTAACATCTCC-3, and second-
stage primers were 5-GACTTGGAGATGTTAGCTGCCGCTGCCGCAGC
Branching assaysGGATGATGAC-3 and 5-GTCATCATCCGCTGCGGCAGCGGCAGCTAA
Assessment of morphogenesis in response to hepatocyte growth factor wasCATCTCCAAGTC-3. The resulting mutant was PCR amplified with primers
performed as described previously (Koochekpour et al., 1999). Briefly, cells5-CGACTCCATGGCTGAAGACACAGAA-3 and 5-AGTCGGGATCCCAAC
were detached by incubation with CellStripper (CellGro) and resuspendedTGATCGAAGGA-3, cut with HindIII and BamHI, and ligated into pEGFP-N3
in Dulbecco’s modified Eagle’s medium with 10% fetal calf serum at 350,000to create the mutant fusion, pEGFP-541–580(M2).
cells/ml. For each flat-bottomed well of a 96-well plate, 60 l of cells wasThe high-expression retroviral vector, pVXY, was a gift from Louis Staudt
mixed 1:1 with Matrigel and allowed to set at 37C for 30 min before adding(National Cancer Institute). pEGFP/541–580 was PCR amplified with primers
120 l DMEM with 10% FCS and 40 ng recombinant hepatocyte growth5-AGTCGGAATTCATGGCTGAAGACACAG-3 and 5-AGTCGCTCGAGT
factor (R&D Systems). Cells were then incubated at 37C for 72–90 hr priorTACTTGTACAGCT-3, incorporating EcoRI and XhoI, respectively. The prod-
to inspection.uct was cut with EcoRI and XhoI and ligated into pVXY to create pVXY/
541–580/GFP. The GFP coding sequence from pEGFP-N3 was excised
Mouse xenograft assayusing EcoRI and NotI and ligated into pVXY to create pVXY/GFP.
Approximately 106 viable cells, as determined by trypan blue exclusion, werePEGFP/541–580(M2) was cut with XbaI and blunt-ended using DNA
suspended in 100 l Hank’s buffered saline and injected subcutaneouslypolymerase 1 Klenow fragment. After precipitation, the linearized vector was
per flank of SCID mice (Taconic). Five to seven 6-week-old female micecut with BamHI and ligated into pVXY between BamHI and a blunted XhoI
were injected with each cell line. Tumors were measured weekly with caliperssite to form pVXY/541–580(M2). Retroviral vectors were transformed in Stbl2
in the two greatest dimensions by a technician blinded to the genotype.competent cells (Life Technologies) and expanded at 30C.
All PCR was performed using Advantage cDNA polymerase mix (Clon-
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